These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 12096355

  • 21. Anagrelide: a novel agent for the treatment of myeloproliferative disorders.
    Pescatore SL, Lindley C.
    Expert Opin Pharmacother; 2000 Mar; 1(3):537-46. PubMed ID: 11249536
    [Abstract] [Full Text] [Related]

  • 22. Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.
    Gilbert HS.
    Oncology (Williston Park); 2001 Aug; 15(8):989-96, 998; discussion 999-1000,1006,1008. PubMed ID: 11548978
    [Abstract] [Full Text] [Related]

  • 23. [Appearance of leg ulcers associated with intake of anagrelide].
    Rappoport L, Körber A, Grabbe S, Dissemond J.
    Dtsch Med Wochenschr; 2007 Feb 16; 132(7):319-21. PubMed ID: 17286219
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
    Penka M, Schwarz J, Ovesná P, Cervinek L, Dulíček P, Pospíšilová D, Kissová J, Pavlík T, kolektiv Ceske pracovni skupiny pro myeloproliferativni choroby (CZEMP).
    Vnitr Lek; 2013 Jun 16; 59(6):516-31. PubMed ID: 23808749
    [Abstract] [Full Text] [Related]

  • 26. Severe hypersensitivity pneumonitis associated with anagrelide.
    Raghavan M, Mazer MA, Brink DJ.
    Ann Pharmacother; 2003 Sep 16; 37(9):1228-31. PubMed ID: 12921504
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
    Prescrire Int; 2006 Jun 16; 15(83):83-6. PubMed ID: 16764090
    [Abstract] [Full Text] [Related]

  • 34. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
    Barbui T, Finazzi G, Dupuy E, Kiladjian JJ, Brière J.
    Leuk Lymphoma; 1996 Sep 16; 22 Suppl 1():149-60. PubMed ID: 8951786
    [Abstract] [Full Text] [Related]

  • 35. [Treatment of essential thrombocythemia].
    Costello R, O'Callaghan T, Sébahoun G.
    Rev Med Interne; 2005 Dec 16; 26(12):947-55. PubMed ID: 16122842
    [Abstract] [Full Text] [Related]

  • 36. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia.
    Laguna MS, Kornblihtt LI, Marta RF, Michiels JJ, Molinas FC.
    Clin Appl Thromb Hemost; 2000 Jul 16; 6(3):157-61. PubMed ID: 10898276
    [Abstract] [Full Text] [Related]

  • 37. Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers?
    Bennett CL, Weinberg PO, Golub RM.
    Semin Hematol; 1999 Jan 16; 36(1 Suppl 2):26-9. PubMed ID: 9930555
    [Abstract] [Full Text] [Related]

  • 38. Anagrelide, a selective thrombocytopenic agent.
    Oertel MD.
    Am J Health Syst Pharm; 1998 Oct 01; 55(19):1979-86. PubMed ID: 9784784
    [Abstract] [Full Text] [Related]

  • 39. Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.
    Santoro C, Sperduti I, Latagliata R, Baldacci E, Anaclerico B, Avvisati G, Breccia M, Buccisano F, Cedrone M, Cimino G, De Gregoris C, De Muro M, Di Veroli A, Leonetti Crescenzi S, Montanaro M, Montefusco E, Porrini R, Rago A, Spadea A, Spirito F, Villivà N, Andriani A, Alimena G, Mazzucconi MG.
    Cancer Med; 2017 Jun 01; 6(6):1233-1239. PubMed ID: 28544749
    [Abstract] [Full Text] [Related]

  • 40. Anagrelide: what was new in 2004 and 2005?
    Petrides PE.
    Semin Thromb Hemost; 2006 Jun 01; 32(4 Pt 2):399-408. PubMed ID: 16810615
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.